Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026)
Jazz Pharmaceuticals' quarterly Other Non-Current Assets came in at $94.7 million in Q1 2026, up 952.34% year-on-year from $9.0 million in Q1 2025, and down 4.34% quarter-over-quarter from $99.0 million in Q4 2025.
Jazz Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $94.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 952.34% year-over-year to $94.7 million; the trailing twelve-month figure through Mar 2026 stood at $94.7 million (up 952.34% YoY), and the FY2025 full-year result was $99.0 million, down 13.52% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $94.7 million, down from $99.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $114.5 million in Q4 2024, with the low at $5.7 million in Q2 2024.
- Average Other Non-Current Assets over 5 years is $49.5 million, with a median of $55.1 million recorded in 2022.
- Year-over-year, Other Non-Current Assets plunged 90.97% in 2024 and jumped 952.34% in 2026.
- Tracing JAZZ's Other Non-Current Assets over 5 years: stood at $55.1 million in 2022, then climbed by 22.35% to $67.5 million in 2023, then jumped by 69.69% to $114.5 million in 2024, then declined by 13.52% to $99.0 million in 2025, then fell by 4.34% to $94.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $94.7 million (Q1 2026), $99.0 million (Q4 2025), and $103.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 94.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.70 Mn |
| Dec 31, 2025 | 99.00 Mn |
| Sep 30, 2025 | 103.07 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 9.00 Mn |
| Dec 31, 2024 | 114.48 Mn |
| Sep 30, 2024 | 75.23 Mn |
| Jun 30, 2024 | 5.74 Mn |
| Mar 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 67.46 Mn |
| Sep 30, 2023 | 76.08 Mn |
| Jun 30, 2023 | 7.87 Mn |
| Mar 31, 2023 | 64.08 Mn |
| Dec 31, 2022 | 55.14 Mn |
| Sep 30, 2022 | 9.95 Mn |
| Jun 30, 2022 | 10.64 Mn |
| Mar 31, 2022 | 35.51 Mn |
| Dec 31, 2021 | 40.81 Mn |
| Sep 30, 2021 | 12.72 Mn |
| Jun 30, 2021 | 47.08 Mn |
| Mar 31, 2021 | 4.72 Mn |
| Dec 31, 2020 | 25.72 Mn |
| Sep 30, 2020 | 5.80 Mn |
| Jun 30, 2020 | 6.35 Mn |
| Mar 31, 2020 | 6.89 Mn |
| Dec 31, 2019 | 47.91 Mn |
| Sep 30, 2019 | 7.97 Mn |
| Jun 30, 2019 | 8.52 Mn |
| Mar 31, 2019 | 9.06 Mn |
| Dec 31, 2018 | 42.70 Mn |
| Sep 30, 2018 | 10.06 Mn |
| Jun 30, 2018 | 78.03 Mn |
| Mar 31, 2018 | 7.14 Mn |
| Dec 31, 2017 | 16.42 Mn |
| Sep 30, 2017 | 8.15 Mn |
| Jun 30, 2017 | 16.64 Mn |
| Mar 31, 2017 | 17.63 Mn |
| Dec 31, 2016 | 14.06 Mn |
| Sep 30, 2016 | 37.76 Mn |
| Jun 30, 2016 | 37.01 Mn |
| Mar 31, 2016 | 6.84 Mn |
| Dec 31, 2015 | 7.21 Mn |
| Dec 31, 2014 | 32.83 Mn |
| Sep 30, 2014 | 13.48 Mn |
| Jun 30, 2014 | 11.14 Mn |
| Mar 31, 2014 | 9.30 Mn |
| Sep 30, 2013 | 6.39 Mn |
| Jun 30, 2013 | 5.50 Mn |
| Mar 31, 2013 | 4.55 Mn |
| Dec 31, 2012 | 3.66 Mn |
| Sep 30, 2012 | 20.41 Mn |
| Jun 30, 2012 | 19.23 Mn |
| Mar 31, 2012 | 385,000.00 |
| Dec 31, 2011 | 87,000.00 |
| Sep 30, 2011 | 83,000.00 |
| Jun 30, 2011 | 152,000.00 |
| Dec 31, 2010 | 335,000.00 |